StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix r&d expenses

Research and development expenses are spending on new products and technology.

Ocular Therapeutix's R&D Expenses for the twelve months ending Jun 30, 2026 was $223.51M, up 30.0% year over year. For fiscal 2025 it was $197.10M, up 54.4% from the year before. Over ten years it grew 22.2% a year on average. The highest annual figure on record is $197.10M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$197.10M+54.4%
FY2024Dec 31, 2024$127.64M+109.0%
FY2023Dec 31, 2023$61.06M+14.2%
FY2022Dec 31, 2022$53.46M+6.7%
FY2021Dec 31, 2021$50.08M+74.5%
FY2020Dec 31, 2020$28.69M-30.2%
FY2019Dec 31, 2019$41.09M+11.3%
FY2018Dec 31, 2018$36.92M+19.5%
FY2017Dec 31, 2017$30.88M+14.1%
FY2016Dec 31, 2016$27.07M+1.7%
FY2015Dec 31, 2015$26.61M+40.9%
FY2014Dec 31, 2014$18.88M+79.5%
FY2013Dec 31, 2013$10.52M-8.9%
FY2012Dec 31, 2012$11.54M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$54.14M+6.0%
Q1 FY2026Mar 31, 2026$66.21M+54.5%
Q4 FY2025Dec 31, 2025$50.80M+23.9%
Q3 FY2025Sep 30, 2025$52.36M+41.3%
Q2 FY2025Jun 30, 2025$51.08M+77.0%
Q1 FY2025Mar 31, 2025$42.86M+106.7%
Q4 FY2024Dec 31, 2024$40.99M+153.1%
Q3 FY2024Sep 30, 2024$37.05M+146.7%
Q2 FY2024Jun 30, 2024$28.86M+91.2%
Q1 FY2024Mar 31, 2024$20.74M+40.6%
Q4 FY2023Dec 31, 2023$16.20M+19.6%
Q3 FY2023Sep 30, 2023$15.02M+9.5%
Q2 FY2023Jun 30, 2023$15.09M+15.2%
Q1 FY2023Mar 31, 2023$14.75M+12.6%
Q4 FY2022Dec 31, 2022$13.54M+7.7%
Q3 FY2022Sep 30, 2022$13.72M+7.9%
Q2 FY2022Jun 30, 2022$13.10M-5.5%
Q1 FY2022Mar 31, 2022$13.10M+19.9%
Q4 FY2021Dec 31, 2021$12.58M+65.0%
Q3 FY2021Sep 30, 2021$12.72M+83.0%
Q2 FY2021Jun 30, 2021$13.86M+72.8%
Q1 FY2021Mar 31, 2021$10.93M+79.2%
Q4 FY2020Dec 31, 2020$7.62M-24.7%
Q3 FY2020Sep 30, 2020$6.95M-32.1%
Q2 FY2020Jun 30, 2020$8.02M-14.8%
Q1 FY2020Mar 31, 2020$6.10M-46.1%
Q4 FY2019Dec 31, 2019$10.13M-1.3%
Q3 FY2019Sep 30, 2019$10.24M+5.7%
Q2 FY2019Jun 30, 2019$9.41M+7.7%
Q1 FY2019Mar 31, 2019$11.32M+37.6%
Q4 FY2018Dec 31, 2018$10.26M+29.7%
Q3 FY2018Sep 30, 2018$9.69M+19.2%
Q2 FY2018Jun 30, 2018$8.75M+7.7%
Q1 FY2018Mar 31, 2018$8.23M+22.3%
Q4 FY2017Dec 31, 2017$7.91M+7.9%
Q3 FY2017Sep 30, 2017$8.13M+42.9%
Q2 FY2017Jun 30, 2017$8.12M–
Q1 FY2017Mar 31, 2017$6.73M–
Q4 FY2016Dec 31, 2016$7.33M–
Q3 FY2016Sep 30, 2016$5.69M–

More Ocular Therapeutix figures

See a number that looks wrong?